Polaryx Therapeutics, Inc. (PLYX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Polaryx Therapeutics reported revenue of $0. Net income was -$9.0M, or -$0.20 per diluted share. Operating activities generated -$3.9M of cash, leaving -$3.9M of free cash flow. At fiscal year end, Polaryx Therapeutics held $5.2M in total assets against $605,000 in total liabilities, including $5.1M of cash and equivalents.
Open the full interactive Polaryx Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Polaryx Therapeutics Key Stats
| Share Price | $1.94 |
|---|---|
| Market Cap | $93.7M |
| 52-Week Range | $1.87 – $35.00 |
| Shares Outstanding | 48.3 million (basic, 2026 Q2) |
Polaryx Therapeutics Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$7.8M |
| Pre-Tax Income | -$9.0M |
| Net Income | -$9.0M |
| Diluted EPS | -$0.20 |
Polaryx Therapeutics Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | -$2.5M | -$1.4M |
| Diluted EPS | -$0.05 | -$0.03 |
Polaryx Therapeutics Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $5.1M |
| Current Assets | $5.2M |
| Total Assets | $5.2M |
| Current Liabilities | $605,000 |
| Total Liabilities | $605,000 |
| Shareholders' Equity | $4.6M |
Polaryx Therapeutics Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$3.9M |
| Cash From Financing | $4.5M |
| Free Cash Flow | -$3.9M |
Figures from Polaryx Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Polaryx Therapeutics financials page for every line item.
Polaryx Therapeutics Company Profile
| Ticker | PLYX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Paramus, New Jersey |
| Incorporated in | Wyoming |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002075320 |
Frequently Asked Questions
What was Polaryx Therapeutics' revenue in fiscal 2025?
Polaryx Therapeutics (PLYX) reported revenue of $0 for fiscal 2025.
What was Polaryx Therapeutics' net income in fiscal 2025?
Polaryx Therapeutics reported net income of -$9.0M for fiscal 2025.
What was Polaryx Therapeutics' earnings per share (EPS) in fiscal 2025?
Polaryx Therapeutics' diluted EPS was -$0.20 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Polaryx Therapeutics generate in fiscal 2025?
Polaryx Therapeutics generated -$3.9M of free cash flow in fiscal 2025.
What was Polaryx Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Polaryx Therapeutics reported revenue of $0.
How many shares of Polaryx Therapeutics are outstanding?
Polaryx Therapeutics reported a weighted average of 48.3 million basic shares outstanding in 2026 Q2.
What is Polaryx Therapeutics' market cap?
Based on its latest closing price, Polaryx Therapeutics (PLYX) has a market capitalization of about $93.7M.
When does Polaryx Therapeutics' fiscal year end?
Polaryx Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Polaryx Therapeutics headquartered?
Polaryx Therapeutics lists its business address in Paramus, New Jersey in its SEC filings.